Indeed, addition of the PI3K inhibitor idelalisib to both in vitro and in vivo ibrutinib-treated CLL cells completely abolished anti-IgM–induced VLA-4 activation. Here, CD40LG is linked to B-cell chronic lymphocytic leukemia.